Ono Pharmaceutical

Focus: Ono Pharmaceutical is a Japanese-based small molecule pharmaceutical company headquartered in Osaka with a focus on innovation-driven drug development. The company operates as an established pharmaceutical manufacturer with a regional and potentially global market presence.

Oncology Neurology Metabolic Diseases Immunology

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Open Jobs

About Ono Pharmaceutical

AI assessmentNot Hiring

No open roles listed right now. Follow Ono Pharmaceutical to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

50 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Real-World Evidence of Effectiveness and Safety of Tirabrutinib in Patients with Relapsed or Refract

Primary Central Nervous System Lymphoma (PCNSL)

N/A

Clinical Trials (1)

NCT06714370Real-World Evidence of Effectiveness and Safety of Tirabrutinib in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma in Taiwan: a Nationwide Study

N/A

Help build intelligence for Ono Pharmaceutical

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Established Japanese pharma player with long operational history and small molecule expertise in a differentiated therapy focus
Opportunity to work within a company with regional strength and potential for international expansion careers
Specialized small molecule competency offers deep technical development experience

Watch Out For

No current active job openings listed, indicating limited near-term hiring momentum
Critical data gaps on financials, pipeline, R&D intensity, and clinical programs prevent full risk assessment

Generated by Claude from Ono Pharmaceutical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

ORENCIA Subcutaneous Injection

Rheumatoid Arthritis

N/A

Clinical Trials (1)

NCT02758769Long-Term Outcomes With Abatacept In Biologic Treatment-Naive Rheumatoid Arthritis Patients In Japanese Clinical Practice Settings

N/A

Orencia

Rheumatoid Arthritis

N/A

Clinical Trials (1)

NCT02600455Use-Results Survey for ORENCIA® Subcutaneous Injection 125mg Syringe 1mL

N/A

A Study to Evaluate Treatment Preferences for Japanese Participants With Muscle-invasive Urothelial

Urinary Bladder Neoplasms

N/A

Clinical Trials (1)

NCT05742867A Study to Evaluate Treatment Preferences for Japanese Participants With Muscle-invasive Urothelial Carcinoma of the Bladder

N/A

A Study of Nivolumab Plus Ipilimumab in Participants With Renal Cell Cancer in the Real World Settin

Advanced or Metastatic Renal Cell Carcinoma

N/A

Clinical Trials (1)

NCT04043975A Study of Nivolumab Plus Ipilimumab in Participants With Renal Cell Cancer in the Real World Setting in Japan

N/A

A Retrospective Observational Study of Nivolumab in Combination With Chemotherapy as Neoadjuvant The

Non Small Cell Lung Cancer NSCLC

N/A

Clinical Trials (1)

NCT07169708A Retrospective Observational Study of Nivolumab in Combination With Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC Patients: Real-World Experience in Taiwan (NEOREAL)

N/A

DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Setting in Japan

Type 2 Diabetes Mellitus

N/A

Clinical Trials (1)

NCT02226822DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Setting in Japan

N/A

Non-Interventional

Head & Neck Cancer

N/A

Clinical Trials (1)

NCT03157674Real-World Evidence and Treatment Patterns: Head and Neck Cancer

N/A

Orencia

Rheumatoid Arthritis

N/A

Clinical Trials (1)

NCT02600468Survey on Long-Term Use of ORENCIA® Intravenous Infusion 250mg

N/A

A Study to Evaluate Nivolumab in Japanese Participants With Muscle-invasive Urothelial Carcinoma

Muscle-invasive Urothelial Carcinoma

N/A

Clinical Trials (1)

NCT05779592A Study to Evaluate Nivolumab in Japanese Participants With Muscle-invasive Urothelial Carcinoma

N/A

Yervoy® Postmarketing Surveillance for Patients in Japan With Unresectable, Malignant Melanoma

Melanoma

N/A

Clinical Trials (1)

NCT02717364Yervoy® Postmarketing Surveillance for Patients in Japan With Unresectable, Malignant Melanoma

N/A

Non-Interventional

Undifferentiated Arthritis

N/A

Clinical Trials (1)

NCT03466814Study of the Safety of Orencia in Japanese Children and Adolescents With Active Juvenile Arthritis of Unknown Origin

N/A

A Study of the Effectiveness and Safety of Nivolumab Plus Chemotherapy in Participants With Untreate

Stomach Neoplasms

N/A

Clinical Trials (1)

NCT05334719A Study of the Effectiveness and Safety of Nivolumab Plus Chemotherapy in Participants With Untreated Advanced/Recurrent Gastric Cancer

N/A

Non-Interventional

Melanoma

N/A

Clinical Trials (1)

NCT03165422A Real-World Study of Ipilimumab Treatment After Nivolumab Treatment in Melanoma in Japan

N/A

A Retrospective Study of the Effectiveness and Safety of Nivolumab in Advanced/Metastatic Non-Small

Non-Small Cell Lung Cancer

N/A

Clinical Trials (1)

NCT03273790A Retrospective Study of the Effectiveness and Safety of Nivolumab in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients in Japan

N/A

A Study to Observe the Treatment Patterns and Outcomes of Patients in Japan With Kidney Cancer That

Renal Cell Carcinoma

N/A

Clinical Trials (1)

NCT03161145A Study to Observe the Treatment Patterns and Outcomes of Patients in Japan With Kidney Cancer That is Unable to be Removed by Surgery or That Has Spread

N/A

ONO-6950

Healthy Adult Subjects

Phase 1

Clinical Trials (1)

NCT01297582Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-6950 in Healthy Adult Subjects

Phase 1

ONO-4685

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT04079062Single Ascending Dose Study to Assess the Safety, Tolerability, PK and PD of ONO-4685 in Japanese and Caucasian Healthy Adult Male Subjects

Phase 1

Regorafenib

Advanced and Metastatic Solid Tumor

Phase 1

Clinical Trials (1)

NCT03406871Regorafenib and Nivolumab Simultaneous Combination Therapy

Phase 1

ONO-4059

Primary Central Nervous System Lymphoma

Phase 1

Clinical Trials (1)

NCT06541665Phase I Study Evaluating Tolerability, Safety, Pharmacokinetics, and Efficacy of Combined ONO-4059 and R-MPV Therapy for PCNSL

Phase 1

ONO-7579

Solid Tumor

Phase 1

Clinical Trials (1)

NCT03182257Study of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid Tumors

Phase 1

ONO-4685

Plaque Psoriasis

Phase 1

Clinical Trials (1)

NCT05332704Safety, Tolerability, PK, PD and Preliminary Efficacy of ONO-4685

Phase 1

ONO-4578

Hormone Receptor-positive Breast Cancer

Phase 1

Clinical Trials (1)

NCT06570031ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer

Phase 1

ONO-5788

Acromegaly

Phase 1

Clinical Trials (1)

NCT03571594A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers

Phase 1

ONO-7913

Metastatic Pancreatic Cancer

Phase 1

Clinical Trials (1)

NCT06532344An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer

Phase 1

ONO-2745 /CNS 7056

Hepatic Impairment

Phase 1

Clinical Trials (1)

NCT01790607An Open-label, Single-dose, Intravenous Administration Study of ONO-2745/CNS 7056 in Subjects With Chronic Hepatic Impairment

Phase 1

ONO-5788

Acromegaly

Phase 1

Clinical Trials (1)

NCT03849872Single-dose Study to Evaluate the Absolute Bioavailability and Mass Balance of ONO-5788

Phase 1

ONO-9054

Ocular Hypertension (OHT)

Phase 1

Clinical Trials (1)

NCT01670266Single and Multiple Dose Escalation and Two-sequence Crossover Study of ONO-9054 in Patients With Ocular Hypertension or Mild Open-angle Glaucoma

Phase 1

NKTR-214

Advanced Cancer

Phase 1

Clinical Trials (1)

NCT03745807An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumors

Phase 1

ONO-4578

Colorectal Cancer

Phase 1

Clinical Trials (1)

NCT06547385Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer

Phase 1

Mogamulizumab

Gastric Cancer

Phase 1

Clinical Trials (1)

NCT02946671Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients

Phase 1

Lenvatinib

Carcinoma, Hepatocellular

Phase 1

ONO-9054

Healthy Adult Subjects

Phase 1

Clinical Trials (1)

NCT01508988Single Dose Escalation Study of ONO-9054 in Healthy Volunteers

Phase 1

ONO-8539

GERD

Phase 1

Clinical Trials (1)

NCT01707901A Study of the Effect of ONO-8539 on Oesophageal Pain Hypersensitivity in Patients With Non-erosive Reflux Disease

Phase 1

Cabiralizumab

Advanced Malignancies

Phase 1

Clinical Trials (1)

NCT03158272A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread

Phase 1

ONO-7475

Metastatic Pancreatic Cancer

Phase 1

Clinical Trials (1)

NCT06532331A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic Cancer

Phase 1

Tirabrutinib

Rheumatoid Arthritis

Phase 1

ONO-8539

Acid Reflux

Phase 1

Clinical Trials (1)

NCT01705275A Study to Investigate the Effect of ONO-8539 on Acid-Induced Oesophageal Hypersensitivity in Healthy Volunteers

Phase 1

ONO-4578

Advanced or Metastatic Solid Tumors

Phase 1

Clinical Trials (1)

NCT03155061Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors

Phase 1

ONO-6950

Healthy Adult Subjects

Phase 1

Clinical Trials (1)

NCT01405651Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-6950 in Healthy Adult Subjects

Phase 1

ONO-7684

Venous Thromboembolism

Phase 1

Clinical Trials (1)

NCT03919890A Two-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-7684 in Healthy Adult Volunteers

Phase 1

ONO-4685

Relapsed or Refractory T Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Phase 1

Clinical Trials (1)

NCT06547528A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL

Phase 1

ONO-7475

Stage IIIB Non-small Cell Lung Cancer

Phase 1

Clinical Trials (1)

NCT06525246Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer

Phase 1

Nivolumab

Locally Advanced Esophageal Squamous Cell Carcinoma

Phase 1

Clinical Trials (1)

NCT03914443A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma

Phase 1

Tirabrutinib

Primary Central Nervous System Lymphoma (PCNSL)

Phase 1

Clinical Trials (1)

NCT07198087A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants

Phase 1

Encorafenib capsule formulation

Healthy

Phase 1

Clinical Trials (1)

NCT05446142A Relative Bioavailability Study Evaluating Two New Encorafenib Formulations

Phase 1

ONO-7913

Unresectable Colorectal Cancer

Phase 1

Clinical Trials (1)

NCT06540261The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer